IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.67
+1.52%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.14
- Revenue estimate
- $1.8M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.14
- EPS estimate
- -$0.16
- Revenue actual
- $755.0K
- Revenue estimate
- $2.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +14.5%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $11
- PT range
- $8.00 – $13
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026